

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>	<b>SERIAL NO.</b> <b>FILING DATE</b> <b>APPLICANT</b> <b>GROUP</b> <b>EXAMINER</b> <b>ATTORNEY DOCKET NO.</b>	<b>To be assigned</b> <b>Concurrently herewith</b> <b>Michael Tolar MARTIN</b> <b>To be assigned</b> <b>To be assigned</b> <b>10/17/2025</b> <b>PU49750USW</b>
---	--	--

## **U.S. PATENT DOCUMENTS**

**Continue on page**

## FOREIGN PATENT DOCUMENTS

**Continue on page**

**OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)**

① 3. Balzarini, "Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy," *Biochemical Pharmacology* 58(1):1-27 (Jun. 1999).

② 4. De Clercq, "Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection," *Il Farmaco* 54:26-45 (1999).

---

**Continue on page**

EXAMINER	<i>a. Pen</i>	DATE CONSIDERED <i>9/16/07</i>
----------	---------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if citation is not considered or is in conformance with MPEP § 609.